A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2019 Apr 6

PMID 30949077

Citations 37

Authors

Ben Sessa

Laurie Higbed

David Nutt

Affiliations

Soon will be listed here.

Abstract

This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issues, and clinical applications of the medicine 3,4-methylenedioxymethamphetamine (MDMA). Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD). In this review paper other potential therapeutic applications for MDMA therapy are described, including contemporary studies treating anxiety associated with autism and the authors' ongoing study exploring the potential role for MDMA-assisted psychotherapy to treat alcohol use disorder. MDMA therapy for PTSD is now entering the final Phase 3 stage of drug development, with a target set for licensing by the FDA and EMA in 2021. This means that if clinical efficacy criteria are achieved, MDMA would become a medicine.

Citing Articles

Licit use of illicit drugs for treating depression: the pill and the process.

Torrado Pacheco A, Moghaddam B J Clin Invest. 2025; 134(12).

PMID: 40047885 PMC: 11178541. DOI: 10.1172/JCI180217.

Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.

Gold N, Podrebarac S, White L, Marini C, Simon N, Mittelman M Psychedelic Med (New Rochelle). 2025; 1(2):87-97.

PMID: 40046728 PMC: 11658675. DOI: 10.1089/psymed.2022.0011.

Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder.

Kaur H, Karabulut S, Gauld J, Fagot S, Holloway K, Shaw H Psychedelic Med (New Rochelle). 2025; 1(3):166-185.

PMID: 40046567 PMC: 11661495. DOI: 10.1089/psymed.2023.0023.

MDMA for treatment of PTSD and neurorehabilitation in military populations.

Dunn W, Bershad A, Krantz D, Vermetten E NeuroRehabilitation. 2024; 55(3):357-368.

PMID: 39331116 PMC: 11612990. DOI: 10.3233/NRE-230270.

Effects of chronic stress on cognitive function - From neurobiology to intervention.

Girotti M, Bulin S, Carreno F Neurobiol Stress. 2024; 33:100670.

PMID: 39295772 PMC: 11407068. DOI: 10.1016/j.ynstr.2024.100670.

References

Mas M, Farre M, de la Torre R, Roset P, Ortuno J, Segura J . Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999; 290(1):136-45. View

Liechti M, Baumann C, Gamma A, Vollenweider F . Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000; 22(5):513-21. DOI: 10.1016/S0893-133X(99)00148-7. View

Rothman R, Baumann M, Dersch C, Romero D, Rice K, Carroll F . Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2000; 39(1):32-41. DOI: 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. View

Liechti M, Gamma A, Vollenweider F . Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl). 2001; 154(2):161-8. DOI: 10.1007/s002130000648. View

Harris D, Baggott M, Mendelson J, Mendelson J, Jones R . Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2002; 162(4):396-405. DOI: 10.1007/s00213-002-1131-1. View

Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse A . Review of deaths related to taking ecstasy, England and Wales, 1997-2000. BMJ. 2003; 326(7380):80-1. PMC: 139936. DOI: 10.1136/bmj.326.7380.80. View

Shulgin A . 3-METHOXY-4,5-METHYLENEDIOXY AMPHETAMINE, A NEW PSYCHOTOMIMETIC AGENT. Nature. 1964; 201:1120-1. DOI: 10.1038/2011120a0. View

Hanson K, Luciana M . Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med. 2004; 34(2):229-46. DOI: 10.1017/s0033291703001132. View

Halpern J, Pope Jr H, Sherwood A, Barry S, Hudson J, Yurgelun-Todd D . Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend. 2004; 75(2):135-47. DOI: 10.1016/j.drugalcdep.2004.02.008. View

10.

Bexis S, Docherty J . Role of alpha2A-adrenoceptors in the effects of MDMA on body temperature in the mouse. Br J Pharmacol. 2005; 146(1):1-6. PMC: 1576257. DOI: 10.1038/sj.bjp.0706320. View

11.

Verrico C, Miller G, Madras B . MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl). 2005; 189(4):489-503. DOI: 10.1007/s00213-005-0174-5. View

12.

Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S . Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci. 2005; 25(49):11489-93. PMC: 6725903. DOI: 10.1523/JNEUROSCI.3984-05.2005. View

13.

Kuypers K, Ramaekers J . Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected. Psychopharmacology (Berl). 2006; 189(4):557-63. DOI: 10.1007/s00213-006-0321-7. View

14.

Domes G, Heinrichs M, Michel A, Berger C, Herpertz S . Oxytocin improves "mind-reading" in humans. Biol Psychiatry. 2006; 61(6):731-3. DOI: 10.1016/j.biopsych.2006.07.015. View

15.

Thompson M, Callaghan P, Hunt G, Cornish J, McGregor I . A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). Neuroscience. 2007; 146(2):509-14. DOI: 10.1016/j.neuroscience.2007.02.032. View

16.

Sessa B, Nutt D . MDMA, politics and medical research: have we thrown the baby out with the bathwater?. J Psychopharmacol. 2007; 21(8):787-91. DOI: 10.1177/0269881107084738. View

17.

Mueller D, Porter J, Quirk G . Noradrenergic signaling in infralimbic cortex increases cell excitability and strengthens memory for fear extinction. J Neurosci. 2008; 28(2):369-75. PMC: 6670514. DOI: 10.1523/JNEUROSCI.3248-07.2008. View

18.

Hsu S, Grow J, Marlatt G . Mindfulness and addiction. Recent Dev Alcohol. 2009; 18:229-50. DOI: 10.1007/978-0-387-77725-2_13. View

19.

Pirona A, Morgan M . An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users. J Psychopharmacol. 2009; 24(2):175-85. DOI: 10.1177/0269881109102780. View

20.

Mithoefer M, Wagner M, Mithoefer A, Jerome L, Doblin R . The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2010; 25(4):439-52. PMC: 3122379. DOI: 10.1177/0269881110378371. View